US measles outbreak tops 2,000 known infections
On Dec. 29, 2025, measles cases nationwide have reached 2,012, the Centers for Disease Control and Prevention (CDC)…
FDA approves Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults
On Dec. 22, 2025, Novo Nordisk announced announced that the US Food and Drug Administration (FDA) has approved…
Novartis and U.S. government reach agreement on lowering drug prices
On Dec. 19, 2025, Novartis, a leading global innovative medicines company, announced it has reached an agreement with…
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases
On Dec. 19, 2025, BioMarin Pharmaceutical and Amicus Therapeutics announced that BioMarin has entered into a definitive agreement…
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
On Dec. 18, 2025, Novo Nordisk announced the submission of a New Drug Application (NDA) to the U.S….
FDA | Medicine | Therapeutics
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
On Dec. 9, 2025, Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the…
Johnson & Johnson to acquire Halda Therapeutics for $3.05 billion, revolutionize treatment of cancer
On Nov. 17, 2025, Johnson & Johnson announced that it has entered into a definitive agreement to acquire…
Merck to Acquire Cidara Therapeutics for $9.2 Billion, Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
On Nov. 14, 2025, Merck and Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, announced that…
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
On Nov. 13, 2025, Legend Biotech announced the official opening and ribbon cutting of its new, state-of-the-art research…
New Jersey man’s death first one to be tied to tick-related meat allergy
On Nov. 13, 2025, a previously healthy New Jersey man has been identified by an allergist at the…
Kimberly-Clark buying Tylenol maker Kenvue in $48.7 billion deal
On Nov. 3, 2025, Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about…
Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
On Oct. 20, 2025, Merck announced the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility…
ACG to invest $200 million in U.S. hard-shell capsule manufacturing
On Oct. 20, 2025, ACG, the world’s most integrated provider of solid-dosage solutions, announced a $200 million phased…
FDA approves Novo Nordisk’s oral semaglutide for cardiovascular risk reduction in adults with type 2 diabetes
On Oct. 17, 2025, Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Rybelsus®, the only oral GLP-1…
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
On Oct. 9, 2025, Celltrion announced announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar…
Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle
On Sept. 30, 2025, Zoetis announced that Dectomax®-CA1 Injectable is the first and only parasite control product to…
Merck to scrap London drug research centre
On Sept. 10, 2025, Merck announced it was scrapping research operations in London, citing the UK’s challenging business…
Johnson & Johnson to Invest $2 Billion at State-Of-The-Art North Carolina Facility
On Aug. 21, 2025, Johnson & Johnson announced it will increase its presence in North Carolina with a…
Biotechnology | Disease | FDA | Therapeutics
FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B
On Jul. 31, 2025, Novo Nordisk announced that the US Food and Drug Administration (FDA) approved Alhemo® (concizumab-mtci)…
Biotechnology | Disease | FDA | Therapeutics
Merck spends $10 billion for Verona, gaining access to its COPD medication
On Jul. 9, 2025, pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases,…
Major autism study uncovers biologically distinct subtypes, paving the way for precision diagnosis and care
On Jul. 9, 2025, researchers at Princeton University and the Simons Foundation have identified four clinically and biologically…
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
On Jul. 7, 2025, Celltrion announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab)…
Hikma Pharmaceuticals announces $1 Billion investment in U.S. Expansion
On Jun. 28, 2025, Hikma Pharmaceuticals USA announced it will invest $1 billion by 2030 to further expand…
CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults overweight or obesity in REDEFINE 1, published in NEJM
On Jun. 22, 2025, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3…
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention RSV Lower Respiratory Tract Disease in Infants
On Jun. 9, 2025, Merck announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for…
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening U.S. presence
On May 22, 2025, Sanofi announces the formal opening of the company’s new flagship U.S. offices, unveiling a…
Disease | FDA | Neurology | Pharmaceutical | Therapeutics
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for Acute Treatment of Migraine
On May 15, 2025, Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya®…
Sanofi to invest $20 billion in U.S. through 2030
On Mar. 14, 2025, Sanofi announced that it plans to invest at least $20 billion in the United…
Scientists complete largest wiring diagram and functional map of the brain to date
On Apr. 9, 2025, a team of neuro scientists scientists published findings from the Machine Intelligence from Cortical…
U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
On Mar. 9, 2025, Celltrion announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and…